Skip to main content
. 2022 Dec 21;18(11):2942–2953. doi: 10.1111/jth.15067

Table 2.

Associations of biological data with 30‐day increase of oxygenation requirements

Biological data 30‐day aggravation
Unadjusted
Adjusteda
No (n = 172) Yes (=71) SHR (95% CI) P SHR (95% CI) P
O blood group, n (%) 56 (42.1) 21 (35.6) 0.78 (0.46‐1.32)b .35 0.80 (0.46‐1.39)b .44
Leucocytes/mm3 7676 ± 3796 7667 ± 3663 .31f .26f
0‐5 daysd 1.12 (0.89‐1.40) .16 1.13 (0.89‐1.43) .32
6‐30 daysd 0.65 (0.31‐1.33) .24 0.66 (0.32‐1.34) .24
Neutrophils/mm3 4700 (3600‐6500) 5350 (4400‐7500) 1.29 (0.96‐1.74)c .090 1.19 (0.88‐1.61)c .24
Lymphocytes/mm3 1109 ± 646 927 ± 485 0.74 (0.54‐1.01) .061 0.71 (0.50‐0.99) .041
Monocytes/mm3 500 (300‐700) 400 (300‐700) 0.97 (0.75‐1.25)c .81 0.91 (0.72‐1.16)c .44
Platelets, G/L 236 ± 120 214 ± 98 .073f .28f
0‐5 daysd 0.94 (0.73‐1.21) .62 0.95 (0.72‐1.24) .69
6‐30 daysd 0.66 (0.45‐0.94) .023 0.66 (0.43‐1.01) .057
Creatinine, mg/L 8 (7‐11) 10 (7‐12) 1.20 (0.95‐1.51)c .12 1.10 (0.83‐1.47)c .48
Lactate dehydrogenase, IU/L 359 (280‐476) 426 (312‐508) 1.22 (0.96‐1.54)c .090 1.11 (0.87‐1.43)c .38
Troponine ng/L 14 (7‐26) 16 (9‐24) .25f .50f
<8 41 (28.1) 10 (17.2) 1.00 (ref.) 1.00 (ref.)
8‐14 33 (22.6) 17 (29.3) 1.90 (0.88‐4.04) .098 1.16 (0.61‐2.18) .65
15‐25 34 (23.3) 18 (31.0) 1.99 (0.93‐4.23) .075 1.19 (0.60‐2.31) .62
>25 38 (26.0) 13 (22.5) 1.36 (0.61‐3.04) .46 0.71 (0.33‐1.53) .38
C‐reactive protein, mg/L 60 (25‐111) 101 (56‐143) 1.68 (1.26‐2.23)c <.001 1.66 (1.25‐2.19)c <.001
aPTT 1.13 (1.00‐1.26) 1.13 (1.06‐1.23) 1.02 (0.85‐1.23)c .82 1.02 (0.84‐1.24)c .85
PTr 1.09 (1.04‐1.16) 1.10 (1.05‐1.18) 1.15 (0.98‐1.35)c .081 1.10 (0.89‐1.38)c .34
D‐dimers, µg/mL 1.00 (0.70‐1.80) 1.00 (0.80‐1.90) 1.04 (0.77‐1.40)c .80 1.01 (0.74‐1.38)c .95
Fibrinogen, g/L 5.9 ± 1.7 6.4 ± 1.5 1.32 (1.04‐1.68) .021 1.34 (1.04‐1.74) .022
Factor VIII, IU/dL 244 ± 104 233 ± 79 0.93 (0.73‐1.17) .51 0.89 (0.71‐1.13) .34
VWF:Age, IU/dL 351 ± 141 381 ± 98 .30f .39f
<270 44 (28.6) 9 (15.5) 1.00 (ref.) 1.00 (ref.)
270‐354 35 (22.7) 17 (29.3) 2.09 (0.94‐4.60) .068 1.71 (0.77‐3.78) .18
355‐430 38 (24.7) 16 (27.6) 1.86 (0.83‐4.14) .13 1.86 (0.87‐3.93) .11
>430 37 (24.0) 16 (27.6) 1.94 (0.86‐4.35) .11 1.80 (0.82‐3.97) .14
FVIII/VWF:Ag ratio 0.74 ± 0.27 0.64 ± 0.24 0.70 (0.52‐0.96) .025 0.71 (0.51‐0.98) .036

Note

Values are median (interquartile range) or means ± standard deviation. SubHazard ratios (SHRs) were calculated using Fine and Gray models taking into account the mortality in the context of withholding or withdrawal of life‐sustaining treatment (n = 16) as competing events and were expressed per one standard deviation unless otherwise as indicated.

Abbreviations: aPTTr, activated partial thromboplastin time ratio; CI, confidence interval; CRP, C‐reactive protein; FVIII, factor VIII activity; PTr, prothrombin time ratio; SD, standard deviation; SHR, subhazard ratio; VWF: Ag, von Willebrand factor antigen.

a

Adjusted for age, sex, body mass index, hypertension, and diabetes calculated after handling missing values (in biological and confounding factors) by multiple imputation.

b

SHR calculated for O versus others blood groups.

c

SHR calculated per one standard deviation in log‐transformed values.

d

Modeled with time‐dependent coefficients to accommodate deviation in proportional subhazard assumption.

e

Modeled as categorical variables based on quartiles to accommodate deviation in log linear relationship.

f

P‐value for overall effect calculated using a likelihood ratio test.